Orismilast

N/A

Report date: 2024/02/22 14:44:12
NME

Base Information

Drug NameOrismilast
Drug Alias NameLEO-32731LEO32731LP-0058IBI-353UNI50001 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsPlaque psoriasisDrug-Related Side Effects and Adverse ReactionsPsoriasis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandHungary +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLeo Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics IncUnion Therapeutics A/SInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesLeo Pharma Inc
Active IndicationsPlaque psoriasisPsoriasisSkin Diseases +[4] 
Inactive IndicationsDrug-Related Side Effects and Adverse ReactionsHidradenitis Suppurativa

Other Information

ATC CodeN/A
Related LinksN/A